RPS Early Careers Pharmacist (ECP) Advisory Group

RPS recognises the importance in both listening and supporting our Early Careers Pharmacists and so launched  the RPS Early Careers Pharmacist (ECP) Advisory Group. The purpose of the group is to provide strong representation to early career pharmacists to ensure that ECPs are recognised as crucial stakeholders in the pharmacy sector across England, Scotland and Wales.  The Advisory Group will serve as a consultative group to the Royal Pharmaceutical Society (RPS), acting as a source of expertise, advice and opinion to inform RPS policy decisions and operational delivery plans.

 

See link here: https://www.rpharms.com/about-us/news/details/Early-Careers-Pharmacist-Advisory-Group—Apply-to-join-now

Latest News

By BOPA Executive Committee on 4th November 2025

Joint BOPA and PASG Position Statement Safer Handling of Hazardous SACT Drugs: A Pharmacy Workforce Position Statement

BOPA and PASG Publish Joint Position Statement on the Safer Handling of Hazardous SACT Drugs The British Oncology Pharmacy Association (BOPA) and the NHS Pharmaceutical Aseptic Services Group (PASG) have…

Read article
By Jennifer Allen - LCC Lead on 4th November 2025

BOPA’s Let’s Communicate Cancer (LCC) series receives re-accreditation from the Royal Society for Public Health (RSPH)

The Let’s Communicate Cancer (LCC) series, available for free on the BOPA website CancerHUB: Home Page – BOPA, has recently received re-accreditation from the Royal Society for Public Health which…

Read article
By BOPA Executive Committee on 3rd November 2025

BOPA’s Submission for the National Cancer Plan for England 2025 – Call for Evidence

With the National Cancer Plan 2025 for England Publication imminent (Shaping the national cancer plan – GOV.UK) – please find BOPA’s Submission for the call for evidence below: BOPA Submission…

Read article
By BOPA IOSIG on 1st November 2025

IOCN UK-wide Survey: Access to Immunosuppressants for ICI Adverse Events

  IOCN UK-wide Survey: Access to Immunosuppressants for ICI Adverse Events Have your say on a critical issue affecting immunotherapy patients across the UK. The IOCN and UKSACT Board have…

Read article